Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease

Sitagliptin is a selective inhibitor of dipeptidyl peptidase 4. Among 36 patients undergoing allogeneic hematopoietic stem-cell transplantation treated with sitagliptin in combination with tacrolimus and sirolimus, acute graft-versus-host disease developed in only 5%, and 1-year nonrelapse mortality...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-01, Vol.384 (1), p.11-19
Hauptverfasser:	Farag, Sherif S, Abu Zaid, Mohammad, Schwartz, Jennifer E, Thakrar, Teresa C, Blakley, Ann J, Abonour, Rafat, Robertson, Michael J, Broxmeyer, Hal E, Zhang, Shuhong
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antigens Cytokines Diabetes Dipeptidyl-peptidase IV Dipeptidyl-Peptidase IV Inhibitors - administration & dosage Dipeptidyl-Peptidase IV Inhibitors - adverse effects Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Down-regulation Drug Therapy, Combination Female Graft versus host disease Graft vs Host Disease - prevention & control Graft-versus-host reaction Hematopoietic Stem Cell Transplantation - adverse effects Humans Immunosuppressive Agents - therapeutic use Insulin Leukemia Leukemia, Myeloid - therapy Ligands Lymphocytes T Male Medical prognosis Middle Aged Mortality Myelodysplastic Syndromes - therapy Peptidase Peripheral blood Plasma Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy Prophylaxis Rapamycin Recurrence Sirolimus - therapeutic use Sitagliptin Phosphate - administration & dosage Sitagliptin Phosphate - adverse effects Sitagliptin Phosphate - therapeutic use Software Stem cell transplantation Stem cells Survival Analysis Tacrolimus Tacrolimus - therapeutic use Transplantation, Homologous Transplants & implants Tumor necrosis factor-TNF Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Sitagliptin is a selective inhibitor of dipeptidyl peptidase 4. Among 36 patients undergoing allogeneic hematopoietic stem-cell transplantation treated with sitagliptin in combination with tacrolimus and sirolimus, acute graft-versus-host disease developed in only 5%, and 1-year nonrelapse mortality was zero.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2027372